A Phase 1 Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment Compared With Healthy Subjects
Latest Information Update: 20 Mar 2023
At a glance
- Drugs Fedratinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 16 Mar 2023 Status changed from recruiting to completed.
- 27 May 2022 Planned End Date changed from 31 Dec 2021 to 10 Nov 2022.
- 27 May 2022 Planned primary completion date changed from 31 Dec 2021 to 10 Nov 2022.